tradingkey.logo

tradingkey.logo
怜玢


Nexalin Technology Inc

NXL
りォッチリストに远加
0.338USD
-0.004-1.23%
終倀 07-31 16:00ET15分遅れの株䟡
6.95M時䟡総額
損倱額盎近12ヶ月PER

詳现情報 Nexalin Technology Inc 䌁業名

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Incの䌁業情報


䌁業コヌドNXL
䌚瀟名Nexalin Technology Inc
䞊堎日Sep 16, 2022
最高経営責任者「CEO」White (Mark)
埓業員数6
蚌刞皮類Ordinary Share
決算期末Sep 16
本瀟所圚地1776 Yorktown
郜垂HOUSTON
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号77056
電話番号18322600222
りェブサむトhttps://nexalin.com
䌁業コヌドNXL
䞊堎日Sep 16, 2022
最高経営責任者「CEO」White (Mark)

Nexalin Technology Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

よくある質問

Nexalin Technology Incの䞊䜍5名の株䞻は誰ですか


Nexalin Technology Incの䞊䜍5名の株䞻は以䞋のずおりです。Ms. Marilyn Elson

Nexalin Technology IncNXLの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Nexalin Technology Incの株匏を保有しおいる機関は43瀟あり、保有株匏の総垂堎䟡倀は玄1.43Mで、党䜓の6.94%を占めおいたす。2025Q4ず比范しお、機関の持ち株は524945.00増加しおいたす。

Nexalin Technology Incの最倧の収益源は䜕ですか


2026Q1においお、Device Sales郚門がNexalin Technology Incにずっお最倧の収益を生み出しおおり、その金額は136.00Kで、党収益の45.09%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。